Xcout Intel
Sail Biomedicines
Sail Biomedicines develops a new class of RNA medicines and in vivo CAR-T cell therapies designed to reset autoimmunity and treat immune-mediated diseases. The company utilizes an integrated platform combining Endless RNA (eRNA) constructs and targeted nanoparticles to deliver protein cargos directly to specific immune cells inside the body.
Subscribe to see Sail Biomedicines’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Sail Biomedicines at a glance
Sail Biomedicines is a biotech company. Xcout tracks 19 named people at Sail Biomedicines, including Gene Marcantonio (Chief Medical Officer). Xcout recorded 13 job postings from Sail Biomedicines in the last 90 days.
Sail Biomedicines leadership
- Gene MarcantonioChief Medical Officer
- Vincent HennemandChief Product Operations Officer
- John MendleinExecutive Chairman
- Ewen CameronSVP, Platform
- Jim NolanSVP, Head of Technical Development Operations
- Michael MingueneauSVP, Head of Immunology
13 more named people on record for Sail Biomedicines, with roles, board committees and tenure — see the full roster →
Hiring at Sail Biomedicines
Xcout recorded 13 job postings from Sail Biomedicines in the last 90 days, from a hiring record Xcout has kept since August 2026.
The weekly hiring trend, the roles and locations behind it — see Sail Biomedicines's hiring signals →
Recent Sail Biomedicines news
Sail Biomedicines competitors
A few of Sail Biomedicines's closest competitors — see the full list of competitors and alternatives →
Blue Marlin Therapeutics is developing a non-viral, in vivo immune-cell engineering platform that combines targeted lipid nanoparticle delivery, genomic integration, and promoter-gated expression. The company aims to provide durable, cell-specific therapies for patients with oncology and autoimmune diseases.
CREATE Medicines is a clinical-stage biotechnology company located in Cambridge, Massachusetts, pioneering in vivo immune programming with RNA.
CPTx is a genetic medicines company that develops in vivo CAR-T therapies for cancer treatment. The company utilizes a proprietary single-stranded DNA (ssDNA) platform combined with lipid nanoparticle delivery systems to create scalable, non-viral genetic therapies.
Ouro Medicines is a biotechnology company headquartered in South San Francisco, California, developing immune reset therapeutics for chronic immune-mediated diseases.
AviSia Therapeutics is a clinical-stage biotechnology company headquartered in Amsterdam, Netherlands, pioneering antigen-specific immunotherapies for autoimmune diseases. Established as a spin-off, the company develops targeted treatments to reprogram immune responses.
Walking Fish Therapeutics develops cell-based therapeutics by engineering B cells to act as protein factories for the treatment of serious diseases, including oncology, regenerative medicine, autoimmune diseases, and rare deficiency diseases. The company utilizes a proprietary B cell platform to deliver various therapeutic proteins such as replacement proteins, immune-inhibitory proteins, and engineered antibodies.
Get Sail Biomedicines's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Sail Biomedicines in Xcout Intel
- 19 named people with titles, LinkedIn and board committees
- Weekly hiring history and the mix of roles behind it
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access